Related Experiment Video
Updated: Jul 30, 2026

The Multi-organ Chip - A Microfluidic Platform for Long-term Multi-tissue Coculture
Published on: April 28, 2015
A Microfluidic Chip-Based Automated System for Whole-Course Monitoring the Drug Responses of Organoids
Kexin Zhang1, Jiyu Xi1, Yadong Wang2,3
1Department of Biomedical Engineering, School of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Abstract:
Tumor patients-derived organoids, as a promising preclinical prediction model, have been utilized to evaluate ex vivo drug responses for formulating optimal therapeutic strategies. Detecting adenosine triphosphate (ATP) has been widely used in existing organoid-based drug response tests. However, all commercial ATP detection kits containing the cell lysis procedure can only be applied for single time point ATP detection, resulting in the neglect of dynamic ATP variations in living cells. Meanwhile, due to the limited number of viable organoids from a single patient, it is impractical to exhaustively test all potential time points in search of optimal ones. In this work, a multifunctional microfluidic chip was developed to perform all procedures of organoid-based drug response tests, including establishment, culturing, drug treatment, and ATP monitoring of organoids. An ATP sensor was developed to facilitate the first successful attempt on whole-course monitoring the growth status of fragile organoids. To realize a clinically applicable automatic system for the drug testing of lung cancer, a microfluidic chip based automated system was developed to perform entire organoid-based drug response test, bridging the gap between laboratorial manipulation and clinical practices, as it outperformed previous methods by improving data repeatability, eliminating human error/sample loss, and more importantly, providing a more accurate and comprehensive evaluation of drug effects.
Insights
This study introduces a microfluidic chip for real-time adenosine triphosphate (ATP) monitoring in patient-derived organoids, enabling dynamic drug response evaluation for personalized lung cancer therapy.
Area of Science:
- Biomedical Engineering
- Oncology
- Microfluidics
Background:
- Patient-derived organoids are valuable preclinical models for predicting ex vivo drug responses.
- Current adenosine triphosphate (ATP) detection methods for organoids are limited to single time points, neglecting dynamic cellular changes.
- Limited organoid availability per patient restricts comprehensive time-point drug testing.
Purpose of the Study:
- To develop a multifunctional microfluidic chip for comprehensive organoid-based drug response testing.
- To enable whole-course monitoring of organoid growth status using a novel ATP sensor.
- To establish a clinically applicable automated system for lung cancer drug testing.
Main Methods:
- Development of a microfluidic chip integrating organoid establishment, culture, drug treatment, and ATP monitoring.
- Integration of a specialized ATP sensor for continuous monitoring of living organoids.
- Automation of the entire organoid drug testing process.
Main Results:
- The microfluidic chip successfully performed all stages of organoid-based drug response assessment.
- The developed ATP sensor enabled the first successful whole-course monitoring of organoid growth.
- The automated system demonstrated improved data repeatability and reduced human error compared to conventional methods.
Conclusions:
- The microfluidic chip-based automated system provides a more accurate and comprehensive evaluation of drug effects on lung cancer organoids.
- This technology bridges the gap between laboratory research and clinical application for personalized medicine.
- Continuous ATP monitoring offers deeper insights into dynamic drug responses in organoid models.
More Related Videos
Related Concept Videos
Therapeutic Drug Monitoring: Drug Analysis Methods
Bioreactor Controls-I
Microbial Biosensors
Automated Microbial Diagnostics

